Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:activeIngredient |
gptkb:Salmonella_typhi_Ty21a
|
| gptkbp:age |
adults and children over 6 years
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J07AP01
|
| gptkbp:boosterInterval |
every 5 years if at continued risk
|
| gptkbp:broadcastOn |
4 doses, every other day
|
| gptkbp:contraindication |
immunocompromised individuals
acute febrile illness |
| gptkbp:countryOfOperation |
gptkb:Canada
gptkb:United_Kingdom gptkb:United_States |
| gptkbp:form |
capsule
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vivotif
|
| gptkbp:indication |
travel to typhoid-endemic areas
|
| gptkbp:manufacturer |
gptkb:Emergent_BioSolutions
|
| gptkbp:mechanismOfAction |
induces immune response against Salmonella typhi
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea abdominal pain headache |
| gptkbp:storage |
refrigerated
|
| gptkbp:usedFor |
prevention of typhoid fever
|
| gptkbp:bfsParent |
gptkb:PaxVax
|
| gptkbp:bfsLayer |
6
|